OvaScience Inc. (OVAS) Given Average Rating of “Hold” by Brokerages
Shares of OvaScience Inc. (NASDAQ:OVAS) have received a consensus rating of “Hold” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $8.00.
Several equities analysts recently commented on the company. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of OvaScience in a research report on Thursday, June 22nd. Zacks Investment Research downgraded OvaScience from a “hold” rating to a “sell” rating in a research report on Saturday, May 13th. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of OvaScience in a research report on Friday, May 12th. Finally, Credit Suisse Group restated an “underperform” rating and set a $1.00 target price on shares of OvaScience in a research report on Tuesday, April 18th.
COPYRIGHT VIOLATION WARNING: “OvaScience Inc. (OVAS) Given Average Rating of “Hold” by Brokerages” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/07/10/ovascience-inc-ovas-given-average-rating-of-hold-by-brokerages.html.
OvaScience (OVAS) opened at 1.52 on Monday. The company’s 50-day moving average price is $1.40 and its 200-day moving average price is $1.60. OvaScience has a 52 week low of $1.25 and a 52 week high of $8.98. The company’s market capitalization is $54.21 million.
OvaScience (NASDAQ:OVAS) last posted its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.38) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.46) by $0.08. The business had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.12 million. OvaScience had a negative return on equity of 61.67% and a negative net margin of 13,227.72%. OvaScience’s revenue was down 56.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.80) EPS. On average, equities analysts forecast that OvaScience will post ($1.60) EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its stake in OvaScience by 1.3% in the fourth quarter. FMR LLC now owns 5,340,442 shares of the biotechnology company’s stock valued at $8,171,000 after buying an additional 66,400 shares during the period. Northern Capital Management LLC boosted its stake in OvaScience by 92.6% in the first quarter. Northern Capital Management LLC now owns 91,865 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 44,175 shares during the period. UBS Asset Management Americas Inc. purchased a new stake in OvaScience during the first quarter valued at approximately $107,000. GMT Capital Corp boosted its stake in OvaScience by 43.6% in the first quarter. GMT Capital Corp now owns 757,114 shares of the biotechnology company’s stock valued at $1,416,000 after buying an additional 229,719 shares during the period. Finally, KCG Holdings Inc. purchased a new stake in OvaScience during the first quarter valued at approximately $375,000. 63.66% of the stock is owned by institutional investors.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.